Unknown

Dataset Information

0

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.


ABSTRACT: The risks and benefits of adding fludarabine to a 2-Gy total body irradiation (TBI) nonmyeloablative regimen are unknown. For this reason, we conducted a prospective randomized trial comparing 2-Gy TBI alone, or in combination with 90 mg/m(2) fludarabine (FLU/TBI), before transplantation of peripheral blood stem cells from HLA-matched related donors. Eighty-five patients with hematological malignancies were randomized to be conditioned with TBI alone (n = 44) or FLU/TBI (n = 41). All patients had initial engraftment. Two graft rejections were observed, both in the TBI group. Infection rates, nonrelapse mortality, and graft-versus-host disease (GVHD) were similar between groups. Three-year overall survival was lower in the TBI group (54% versus 65%; hazard ratio [HR], .57; P = .09), with higher incidences of relapse/progression (55% versus 40%; HR, .55; P = .06), relapse-related mortality (37% versus 28%; HR, .53; P = .09), and a lower progression-free survival (36% versus 53%; HR, .56; P = .05). Median donor T cell chimerism levels were significantly lower in the TBI group at days 28 (61% versus 90%; P < .0001) and 84 (68% versus 92%; P < .0001), as was NK cell chimerism on day 28 (75% versus 96%; P = .0005). In conclusion, this randomized trial demonstrates the importance of fludarabine in augmenting the graft-versus-tumor effect by ensuring prompt and durable high-level donor engraftment early after transplantation.

SUBMITTER: Kornblit B 

PROVIDER: S-EPMC3755028 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4332717 | BioStudies
2019-01-01 | S-EPMC6451676 | BioStudies
2017-01-01 | S-EPMC5726600 | BioStudies
2015-01-01 | S-EPMC4603747 | BioStudies
2014-01-01 | S-EPMC3996925 | BioStudies
2015-01-01 | S-EPMC4489995 | BioStudies
2019-01-01 | S-EPMC6616257 | BioStudies
2012-01-01 | S-EPMC3448791 | BioStudies
2014-01-01 | S-EPMC4221788 | BioStudies
2015-01-01 | S-EPMC4463740 | BioStudies